Substance Use Disorder and Cognitive Impairment.

Wei Li, Isaiah Chamoun, Suruchi Ghaiye, Vy Ha, Rebecca Billings

Abstract readReview

In one paragraph

Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei LiDepartment of Clinical and Diagnostic Sciences, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-7530-4872

Isaiah ChamounDepartment of Clinical and Diagnostic Sciences, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Suruchi GhaiyeDepartment of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0006-9268-7103

Vy HaDepartment of Clinical and Diagnostic Sciences, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Rebecca BillingsDepartment of Clinical, Academic, & Research Engagement, Lister Hill Library of Health Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-5203-7217

Funding

HRSA HHS D57HP40200

6 · The paper itself

Abstract

(1) Substance use disorder (SUD) is a global issue, which affects people for their physical and mental health. However, it remains unclear about how SUD is associated with cognitive impairment. (2) A literature search was performed across PubMed, Web of Science, and Google Scholar using keywords: cognitive impairment, cognitive dysfunction/prevention and control, behavior, addictive/prevention and control, substance use disorder, addictive/rehabilitation, and recovery. Data from 20 original research studies were extracted to analyze how SUD is associated with cognitive functions. (3) All substances, including tobacco, are associated with a measured decrease in cognitive function in at least one domain. The longer the duration of substance use, especially if multiple substances were used concurrently, the worse the cognitive performance. Abstinence, targeted medication, or cognitive remediation therapy can be used to treat SUD and associated cognitive impairments. (4) Cognitive function should be a focus for rehabilitation programs. For people with SUD, cognitive impairments may hinder them from seeking available treatment options. On the other hand, improved cognitive function may increase the possibility of successful rehabilitation for people with SUD.

Indexed as

cognitioncognitive impairmentsubstance use disorder (SUD)

Identifiers

PMID42795308

DOI10.3390/life16091443

PMCPMC13608821

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.